Topelia has established strong partnerships with world-renowned experts who bring specialised knowledge and robust resources. These collaborations will play a crucial role in guiding the development of Topelia's proprietary TPL101 Antiviral Triple Therapy (ATT) for treating coronavirus infections.

Why work with us

Topelia is developing and commercialising its proprietary TPL101 Antiviral Triple Therapy (ATT) for coronavirus infection.